Recent Transactions

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

06-Feb-20
$NA
Brazil flag
Target: 

Locaweb Serviços de Internet S.A.

flag not available
Acquiror: 
N/A

Advised Locaweb, a pioneer in B2B tech solutions for businesses digital transformation in Brazil with 2 main pillars: BeOnline/SaaS and Commerce

03-Feb-20
$650 million
United States flag
Target: 

Clover Wireless

flag not available
Acquiror: 
First Lien Term Loan B Lenders

Advised Ad Hoc Group of First Lien Term Loan B Lenders on the restructuring of 4L Holdings Corporation 

16-Oct-19
$165 million
Germany flag
Target: 

Mann+Hummel

flag not available
Acquiror: 
N/A

Advised Mann+Hummel, a leading global filtration company, on the placement of a green bonded loan

31-Oct-17
$2.0 billion
South Africa, Switzerland flags
Target: 

Hirslanden Private Hospital Group

flag not available

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

16-Mar-16
$942 million
United States flag
Target: 

Rofin-Sinar Technologies, Inc.

United States flag
Acquiror: 
Coherent, Inc.

Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers

17-Dec-15
$130 million
Swiss, Netherlands flags
Target: 

Airopack Technology Group AG

United States flag
Acquiror: 
Apollo Global Management, LLC

Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV

24-Feb-15
$NA
Luxembourg flag
Target: 

Azelis Group (majority owned by 3i)

United Kingdom flag
Acquiror: 
Funds advised by Apax Partners

Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners

31-Jul-13
$NA
Germany flag
Target: 

Schenck Process Holding GmbH

Advised Schenck Process Holding GmbH, a global leader in bulk material handling, providing applications incorporating weighing, feeding, screening and automation solutions, on the establishment and implementation of a refinancing solution leading to the amendment and extension of its existing senior and mezzanine syndicated facilities

26-Apr-13
$313 million
Belgium flag
Target: 

Azelis S.A.

Advised Azelis S.A., a Pan-European distributor of specialty chemicals owned by funds managed by 3i plc, on its covenant reset and a two year maturity extension of its €240mm syndicated debt package

23-Nov-12
$NA
Sweden flag
Target: 

SAS Group

Norway flag
Acquiror: 
Norwegian Government

Advised the Norwegian Government in relation to some specific issues in connection with the restructuring of SAS, the leading airline group in Northern Europe

01-Aug-12
$4.0 billion
South Africa, Switzerland flags
Target: 

Mediclinic International Limited

Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

show all